What was the overall market valuation of the US malignant lymphoma market in 2024?

The overall market valuation was $1.14 Million in 2024. Read More

What is the projected market valuation for the US malignant lymphoma market by 2035?

The projected valuation for 2035 is $2.25 Million. Read More

What is the expected CAGR for the US malignant lymphoma market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.39%. Read More

Which companies are considered key players in the US malignant lymphoma market?

Key players include Roche, Novartis, Bristol-Myers Squibb, Gilead Sciences, Merck & Co., Amgen, Celgene, Takeda, and AstraZeneca. Read More

What are the market segments for the US malignant lymphoma market based on type?

The market segments based on type include Hodgkin lymphoma and Non-Hodgkin lymphoma. Read More

What were the valuations for Hodgkin lymphoma and Non-Hodgkin lymphoma in 2024?

In 2024, Hodgkin lymphoma was valued at $0.34 Million, while Non-Hodgkin lymphoma was valued at $0.8 Million. Read More

What treatment options are available in the US malignant lymphoma market?

Available treatment options include Radiation therapy, Chemotherapy, Immunotherapy, Stem cell therapy, and Others. Read More

What were the valuations for different treatment options in 2024?

In 2024, Radiation therapy was valued at $0.2 Million, Chemotherapy at $0.4 Million, Immunotherapy at $0.3 Million, Stem cell therapy at $0.1 Million, and Others at $0.14 Million. Read More

How does the market for Chemotherapy compare to Immunotherapy in 2024?

In 2024, Chemotherapy was valued at $0.4 Million, while Immunotherapy was valued at $0.3 Million, indicating a higher valuation for Chemotherapy. Read More

What is the anticipated growth trend for the US malignant lymphoma market in the coming years?

The market appears to be on a growth trajectory, with a projected increase to $2.25 Million by 2035. Read More

US Malignant Lymphoma Market

US Malignant Lymphoma Market Research Report By Type (Hodgkin lymphoma, Non Hodgkin lymphoma) and By Treatment (Chemotherapy, Radiation therapy, Immunotherapy, Stem cell therapy, Others) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.39%

2024 Market Size

$ 1.14 Million

2035 Market Size

$ 2.25 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/18429-HCR | Pages: 100 | Author: Nidhi Mandole, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
  1. 4.1.1 Hodgkin lymphoma
  2. 4.1.2 Non-Hodgkin lymphoma
2. 4.2 Food, Beverages & Nutrition, BY Treatment (USD Million)
  1. 4.2.1 Radiation therapy
  2. 4.2.2 Chemotherapy
  3. 4.2.3 Immunotherapy
  4. 4.2.4 Stem cell therapy
  5. 4.2.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Celgene (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Takeda (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
7. 6.7 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
8. 6.8 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
9. 6.9 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
10. 6.10 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
11. 6.11 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Malignant Lymphoma Market Segmentation

US Malignant Lymphoma Market By Type (USD Million, 2025-2035)

Hodgkin lymphoma
Non-Hodgkin lymphoma

US Malignant Lymphoma Market By Treatment (USD Million, 2025-2035)

Radiation therapy
Chemotherapy
Immunotherapy
Stem cell therapy
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”